Category Archives: LEDs

Click here to enlarge image

July 10, 2003 – Leon Hirsch started the demonstration by exposing a strip of raw skinless chicken breast to a laser. The slab remained shiny pink as a beam of near infrared light penetrated the flesh. He picked up the chicken, poked it with a syringe and injected a liquid into its center.

Click here to enlarge image

Repositioned and re-exposed, the flesh under the beam began to smoke and turn white as the liquid — a formula containing gold shells each slightly larger than a polio virus — absorbed the light, heating to a high enough temperature to cook nearby cells. “It’s actually on fire now,” Hirsch said 10 seconds later, adding that the concentration of nanoshells and the light intensity were both exaggerated for the demonstration.

Click here to enlarge image

In animal studies, nanoshells target cancer cells, not chicken meat, and the beam leaves the skin and healthy flesh unscathed while the shells’ heat damages only tumors. A doctoral student at Rice University, Hirsch is part of a team led by physicist Naomi Halas and bioengineer Jennifer West that is designing nanoshell particles for detecting and treating cancer. Halas and West co-founded the company Nanospectra Biosciences in 2001 in Houston to commercialize nanoshells for cancer and other medical applications.

Nanoshells are one of several nanoscale materials being developed as intravenous and topical drugs. The smorgasbord includes carbon spheres called fullerenes used by the startup C Sixty in Houston for arresting neurodegenerative diseases, and nanoparticles under study by the drug companies Advectus Life Sciences Inc. in Vancouver and American Pharmaceutical Partners in Los Angeles for treating cancers.

Some nanomaterials have a chemical makeup similar to traditional pharmaceuticals, but they perform better because of their greater surface-to-volume ratio. Others are made of biocompatible elements like gold and carbon that do extraordinarily nonbiological tasks — like neutralize cell-damaging substances or absorb or emit light for noninvasive, precise diagnostics and therapies. 

“The wonderful thing that all these beautiful bottom-up nanotechnologies are doing is allowing the conventional idea of material and device to merge,” said Halas, who invented nanoshells in the mid-1990s. “That’s perfect for some of the biological things that we’re doing.”

Girish Solanki, an industry manager for Frost and Sullivan’s Technical Insights group and author of a 2003 market report on nanotechnology, identified biotechnology and electronics as the most promising nanotech applications. But he said about 98 percent of the work is still in the research and development stage.

Metallic nanoshells’ material, size, core and shell thickness determine how each interacts with light. At about 100 nanometers, gold nanoshells can absorb or reflect light in the near infrared range. Blood and tissue, on the other hand, do not absorb near infrared light and are essentially transparent at that wavelength. Nanoshells also easily traverse the body’s circulatory system.

The Rice team gets nanoshells to congregate on cancer cells by attaching specific antibodies or peptides to the shells. The antibodies lock onto the cancer cells; the more cells the more shells accumulate. Irradiated by an external laser, the nanoshells display where they are and in what concentration. The nanoshells also act as a lens, Halas said, focusing light onto themselves for a potent and controlled heat source that can selectively destroy nearby cells.  
   
“We have a seamless integration of cancer detection and therapy,” said Halas, who recently received a $3 million innovator award to develop breast cancer applications as well. “We have identification and all-optical biopsy, but we also have the option of turning up the light a little bit and locally heating the nanoshells to a temperature (that) … will kill the cells that are in the direct vicinity of the nanoshells.”

Nanospectra Biosciences President J. Donald Payne said the cancer program could progress from animal to clinical trials in about 18 months. Further studies likely will include its collaborator, the University of Texas’ M.D. Anderson Cancer Center in Houston. The company also is likely to partner with a pharmaceutical company, which will offer experience with marketing and distribution.

“The kiss of death for most small (biotech) companies is trying to launch a product on your own,” he said. “It takes a significant amount of money.”

Like nanoshells, fullerenes look attractive for medical applications ranging from cancer and HIV treatments to free radical scavengers. Also known as buckyballs, fullerenes are made of 60 carbon atoms that form a soccer ball shape that can ferry virus-crippling compounds, for instance.

C Sixty is concentrating on what it deems its standout application as an antioxidant, taking advantage of fullerenes’ unusual ability to trap cell-damaging free radicals, said Ross Lebovitz, C Sixty’s vice president of business development. Free radicals, or atoms and molecules with unpaired electrons, are a byproduct of reactions with oxygen and other processes. They tend to be highly reactive and have been linked to the onset and progression of fatal neurodegenerative diseases like amyotrophic lateral sclerosis, commonly known as Lou Gehrig’s disease.  

“They have this flexible electron cloud that allows the fullerene to accept electrons and remain stable,” said Lebovitz, a molecular biologist and veteran entrepreneur. “In vitro and it looks like in vivo, this is one of the best antioxidants ever found.”

While fullerenes may not reverse damages from neurodegenerative diseases, they might arrest the diseases’ progression. Taken before onset, they might serve as a preventative. The company also is considering a topical fullerene-based antioxidant that could be used as a therapeutic skin care product, one that might reduce the potential cancer-causing damage of sunburn, for instance. As a topical treatment, fullerenes might face less of a regulatory hurdle and find a quicker path to the marketplace, Lebovitz said.

“We look at each opportunity,” he said. “We want to make the world better, and increase the value of our company. The two go hand in hand.” 

July 3, 2003 – Worldwide sales of semiconductors totaled $12.50 billion in May, up 2.0% from $12.26 million in revenues in April 2003 and a 9.9% increase from May 2002 revenue of $11.38 billion, according to data from the Semiconductor Industry Association (SIA). The total revenue is the highest in four months. The April figures were revised upwards from SIA’s earlier estimates of $12.14 billion, which would have been essentially flat growth from March to April.

SIA President George Scalise said that as the SARS epidemic and geopolitical issues come under control, “We expect to see demand in all geographic sectors, especially China, strengthen in the second half of the year.”

Sector sales figures were up across the board. Sales of programmable logic and standard cell chips increased 8.6% in May, possibly indicating the start of an anticipated pickup in telecom spending, according to the SIA. Flash memory sales were up 4.4%, compared with less than 1% gain in April, and ASSPs were up 3.7% in May, down from 6% growth in April. DRAM sales rebounded from a 5.1% drop in April to a 2.5% gain in May. Optoelectronics sales, at 2.5% in April, spiked to 6.3% in May.

In a year-by-year comparison, Japan led the way with a 26% increase in sales, with Asia Pacific up 11.7%, and Europe up 9.3%. Sales in the Americas declined by 6.7%, largely attributable to the continued trend of outsourcing electronic equipment production to Asia.

Dynamic Wiping Efficiency and Particle Removal Ability tests set out to solve the illusive “in use” conditions need

By J.M. Oathout and Russell L. Bromley

While wipers and other consumable products are critical to the maintenance and function of an effective cleanroom environment, these products have the potential to contaminate the very environment they're meant to protect.

Fully understanding this old adage, test methods developed in the mid-1980s were aimed at determining the potential of consumables to compromise the cleanroom's integrity. In most cases, the methods used to evaluate cleanroom compatibility were originally designed to monitor product quality and consistency. These methods provided information about the wiper materials' physical characteristics or, in some cases, the product's maximum potential to generate contamination when subjected to extreme test conditions.

Rarely, if ever, did the test conditions attempt to simulate the product's actual use conditions. Given the broad range of applications for cleanroom consumables, it's understandable why a set of reproducible “in use” conditions had not been developed.

But without test methods and conditions that simulate actual “in use” conditions, test data cannot predict how a product will actually perform.

It was this complexity that led to the development of two new testing procedures: Dynamic Wiping Efficiency (DWE) and Wet Particle Removal Ability (WPRA). Both aim to simulate how efficiently a wiper removes liquid from a surface, and how effectively that wiper removes particles contained in liquid.

The Dynamic Wiping Efficiency test

One of the critical functions of a cleanroom wiper is to clean up small volume spills. This function is common across virtually all industries that use wet processes in a cleanroom environment.

The purpose of the DWE test procedure is to determine the ability of various wiping materials to sorb and remove spilled liquids.

Nine cleanroom wiper materials were selected for the development of this test. The composition, basis weight and construction of each can be found in Table 1. These wipers represent nearly the full gamut of materials and fabrics commonly used for cleanroom wipers today, and represent a spectrum of composition, construction and cost.

Also shown is the inherent “Po static” particle burden of easily releasable particles, 1.0 to 3.0 µm (microns) per unit area as determined by IEST-RP-CC004.2.3

This size range was reported because particles in this same size range were chosen to create a known challenge to the wiping materials.

Click here to enlarge image

null

DWE test method:The test, conducted in an ISO Class 4 or better laminar flow, utilizes a mechanical apparatus and procedure designed to simulate how a cleanroom wiper is commonly employed:

  • The maximum sorptive capacity of each material is determined by weighing a sample of the fabric, immersing the sample in filtered de-ionized (DI) water, allowing it to drip for 60 seconds, weighing the sample again and subtracting the dry weight from the wet mass.
  • Individual samples of each wiping material are quarter-folded and attached with a clip to the convex leading edge of a one-kilogram test fixture—a stainless steel sled. The sled's dimensions and mass were selected to simulate the surface area and pressure applied by a human hand during wiping.
  • Each wiper is challenged with increasing amounts of 0.2-µm filtered reverse osmosis DI water in a range of volumes up to 130 percent of the wiper's capacity as determined above. This is done to challenge each wiper fabric over a broad range of potential use conditions. For accuracy and reproducibility, the liquid is dispensed with a digital burette and placed directly in front of the sled and wiper, resting in a stainless steel pan, 50-cm outside the longest dimension.
  • The sled is pulled at a speed of ~25 centimeters per second, through the “spill” and across a previously cleaned stainless steel surface (36-cm free area in front of sled). The speed and distance were selected to simulate the wiping action when cleaning a tabletop or bench.
  • The wetted wiper is then carefully removed and promptly weighed. The mass of the liquid picked up is calculated by subtracting the mass of the dry wiper. The volume of water picked up by the wiper can be calculated by dividing the mass of water retained by the density of water (0.997g/mL).

Results: Figures 1 and 2 reveal how “thirsty” each wiper material is and how effective it is in picking up the entire spill. In other words, it compares the wipers' abilities to pick up a given volume of liquid from a surface, regardless of the mass of the wiper itself (a “mattress,” for instance, will pick up more than a “tissue paper”).

Click here to enlarge image

null

Figures 3 and 4 demonstrate which materials maintain good “pick up” ability even when nearing their saturation point. It compares a wiper's ability to remove liquid from a surface versus its individual sorbency potential.

Click here to enlarge image

null

Materials constructed from hydrophilic fibers demonstrate superior DWE or “wipe-dry” than those constructed from hydrophobic fibers (with residual surfactant on fabric left from a laundering operation). In addition, they maintain better “wipe-dry” characteristics, up to their sorptive capacity, than those made from hydrophobic fibers. This is not surprising, since it is certainly possible to “squeeze” the water out of the matrix of fibers in much the same way water is squeezed from a sponge.

Wet Particle Removal Ability (WPRA)

As an enhancement to the DWE test, particles were added to the liquid challenge to determine the effectiveness of each wiper material in retaining and removing a known quantity of particles.

Polystyrene latex spheres (PSL) of 1.59-µm diameter were selected, since they are readily available in a known concentration, uniform in size and shape, and can be easily and reproducibly deposited with a microliter syringe and counted using a liquid particle counter. In fact, this consistency appears to be a quick reliable way to validate particle counter stability over time.

Wet Particle Removal Ability test method: The same test procedure used for the DWE, except that 10 million polystyrene latex spheres are added to the liquid in front of the sled. This large number of particles was selected to ensure that contamination remaining after wiping was well above the blank, thus improving both reproducibility and particle counting accuracy.

In addition, this large quantity was selected in an attempt to challenge the capacity of the wiper fabric to retain and remove particles (Note: Dynamic Wiping Efficiency and Wet Particle Removal Ability should be conducted simultaneously.):

  • Once the wiper and sled are removed from the stainless steel surface, the surface is rinsed with a known volume of filtered DI water. The liquid is then analyzed using a liquid particle counter and the number of particles remaining on the surface is determined.
  • Once again, each wiper is tested using increasing volumes of water, up to and including 130 percent of the wipers' sorptive capacity.

Results: In Figures 5 and 6, data is plotted to show WPRA versus the volume of liquid. Almost every wiper fabric demonstrates fairly good ability to remove particles up to a certain point. Beyond that point, however, the ability to retain and remove particles falls off rapidly.

Click here to enlarge image

null

This is further illustrated in Figures 7 and 8 where WPRA is plotted against the percent of the wipers' capacity. What becomes evident is that the ability of all cleanroom wipers to retain and remove particles is compromised when the volume of solution exceeds 80 to 90 percent of their sorptive capacity. Some wipers exhibit relatively poor WPRA at much lower levels of their sorbent capacity. This has implications both regarding spill clean-up and when solutions are applied to dry wiper materials for cleaning purposes.

Click here to enlarge image

null

Figures 9 and 10 show the number of particles left on the surface as a function of DWE. The data shows that the higher the percentage of liquid removed, the lower the number of particles left behind.

Click here to enlarge image

null

What becomes evident is that the number of particles left on a surface is largely dependent on the quantity of liquid left behind by the wiping process. Thus, to maximize particle removal, it becomes critical not to overload the wiper with liquid.

Wipe dry, wipe clean

The selection of a cleanroom wiper is based largely on its perceived initial cleanliness, not how well it cleaned a surface. It was somewhat surprising to see the high percentage of particles that are retained by the wiper fabric in spite of the enormous challenge of 10 million particles.

Every cleanroom wiper tested removed significantly more particles than would be predicted using DWE alone.

For example, if the DWE is 80 percent, then 20 percent of the liquid would be left behind. With a particle challenge of 10 million, one would expect 2 million particles to be left on the surface. In fact, for most cleanroom wipers, the actual quantity left is 10 percent or less of that number.

The exception is polyester knits, which left a much higher percentage of the particle challenge than the other fabrics, under equivalent test conditions. If this disproportionate removal of particles is viewed as sort of a filtration process where particles are trapped in the wiper's fibrous structure, it is likely that the knits' poorer performance may be due to their more compact yarn structure and to the larger denier of filaments found in the knits versus the non-woven fabrics tested.

When considering the data from WPRA testing, it's also important to understand the amount of contamination contributed by the wiper in the wiping process. This can't be accomplished by conventional test methods that soak the wiper in a pool of water (with or without agitation) or surfactant, since they do not simulate use.

With this in mind, we modified the WPRA test to measure the amount of contamination generated by each wiper fabric in the wiping process.

Particle Contribution test method: In this test, the same procedure is followed as in the DWE test, again using increasing quantities of filtered DI water, up to 130 percent of each wiper's capacity. But no particles are deliberately added to the liquid challenge, as done in the WPRA test.

Once the wiper and sled are removed, filtered DI water is added to the stainless steel tray and the particles are counted as in the WPRA test. In this case, the only particles collected are those coming from the wiper material itself. This method is derived from one presented by Mattina, McBride, Nobile and Turner.2

Results: These data, taken together, reveal:

  1. The particle release from actual dynamic wiping does not parallel the data from conventional (static) methods;
  2. The particle contribution to wetted surfaces is much lower than suggested by current recommended practices (or conventional tests), which attempt to enumerate the particle extracted from a wiper at various levels of mechanical stress.

Conclusions

The data demonstrated that cleanroom wipers made from fabrics that have an exceptional ability to “wipe the surface dry” leave the surface cleaner than those that do not, since the residual contamination resulting from a spill always lies suspended in the liquid phase left behind on the wiped surface.

The overwhelming conclusion from these data is that wipe-dry is not merely a desirable feature in a cleanroom wiping material from a housekeeping point of view, but is a critical feature in wiping up spills of contaminated liquids.

James Marshall Oathout is a Senior Research Associate with DuPont in Old Hickory, Tenn. He serves on Working Group 4 (Wipers) of the Institute of Environmental Sciences, the Standard Test Committee of INDA (Association of Nonwoven Manufacturers), and ASTM Textile sub-committee D13.64. He has authored three standard test methods for INDA and four for ASTM. He can be reached at: [email protected] RUSSELL L. BROMLEY is founder of Regent Technology, Redwood City, Calif.—a management consulting practice specializing in technology and market assessment, strategic planning, channel development and technology transfer. He is a senior member of IEST, having served on numerous RP committees. He can be reached at: [email protected]

References

  1. Oathout, J. M. “Determining the Dynamic Efficiency of Cleanroom Wipers for Removal of Liquids and Particles from Surfaces, Journal of the IEST, V. 42, No. 3, p. 17 (1999)
  2. Mattina, C. F., McBride, J., Nobile, D. and Turner, K., “The Cleanliness of Wiped Surfaces: Particles Left Behind as a Function of Wiper and Volume of Solvent Used,” Proceedings, CleanRooms '96 East, 183 (1996).
  3. “Evaluating Wiping Materials Used in Cleanrooms and Other Controlled Environments”, IEST-RP-CC004.2, Institute of Environmental Sciences and Technology, 940 East Northwest Highway, Mount Prospect, IL 60056, 1992.
Click here to enlarge image

WASHINGTON, June 20, 2003  — It wasn’t a headline that the scientist liked much: “Clayton Teague Thinks Small,” blared the North Texas State University (now the University of North Texas) student newspaper.

That was 1968, and Teague was a graduate student at the time. Now, he’s the first full-time director of the federal National Nanotechnology Coordination Office  (NNCO), and he’s thinking even more infinitesimally. Teague has spent his career helping the federal government explore the world at the nanoscale. The visible contours of that world have grown during Teague’s more than 30 years of federal service, thanks in part to his work.

Click here to enlarge image

Teague is a white-goateed, compact man with a friendly Georgia lilt to his deep voice and a healthy laugh. The University of North Texas physics Ph.D. has devoted his life to nanoscale metrology and quantum tunneling, serving as editor in chief for a decade of the journal Nanotechnology, where he currently sits on the editorial board. The research, including a host of publications and patents, has all been done during his long career with what is now called the National Institute of Standards and Technology (NIST). Before starting his new assignment with the NNCO April 15, he was chief of NIST’s Manufacturing Metrology Division.

During an interview at his National Science Foundation office in Arlington, Va., he championed nanotechnology as a great potential economic and social balm for the nation, and he pledged to use his office to help knit together the many scientific and research threads comprising nanotechnology today, from simulation and modeling to biotechnology to materials science.

These are interesting times for the federal government’s role in nanotechnology. Since President Bill Clinton launched the National Nanotechnology Initiative (NNI) in 2000, the program has more than quadrupled in size, in terms of federal dollars poured into the science. Both houses of Congress have held multiple nanotechnology hearings, and they are pushing along bills that would cement the NNI in the federal bureaucracy and launch new initiatives, including the creation of a research center that would examine environmental, health and social aspects of nanotechnology.

The White House Office of Science and Technology Policy has grown sharply interested in the NNI, in part because of the ballooning amount of nanotechnology spending that it tracks, which is approaching $1 billion. That heightened oversight has led to demands that the NNI produce more results. At a June meeting, members of the Presidents Council of Advisors on Science and Technology  urged the NNI to devote at least part of its administrative energy to finding an inspiring central goal for nanotechnology research, something akin to sending a man to the moon.

Teague sits smack in the center of this mounting whorl of federal activity.

He got a sense of how demanding the job would be during his first week, when a Senate staffer called him to testify the following week at a hearing.

“That was a big deal to me,” said Teague in his spare office, where boxes were still unpacked. “It was the first time I had ever given testimony before Congress. It was a totally new experience, and it was the second week on the job.”

Teague is the perfect leader for the job because, among other things, “he’s very organized,” said NNI director Mike Roco. “That will help because the activity (surrounding nanotechnology) is becoming very intense.”

Teague spends his days meeting with congressional and White House staffers to talk about nanotechnology policy. He also listens to a lot of people in different agencies working on nanotechnology projects, and Teague views this work as a primary responsibility, at least for now.

He said he wants his office to “make sure we give them good representation” in the White House.

In addition, nanotechnology is unusually multidisciplinary, and for the federal government to realize the science’s potential, agencies are going to have to pool resources and work together.

Teague is concerned about the public perception of nanotechnology, and he plans to use the office to educate people about the science. While many tout the promise of nanotechnology, critics point to the science’s unknown environmental and social consequences. 

“The scientific community will address this in a very, very direct way, and if materials are being introduced into the environment or the workplace, standard procedures that are now in place” to deal with other elements will be applied to nanoparticles.

“Right now almost all of the studies that have been done, where they look at (the toxicity of nanoparticles), are preliminary and certainly of a nonconclusive nature,” he said. “It would be too early to draw any conclusions about any undue levels of toxicity. There is not enough evidence to believe that these things are unusually toxic.”

Mark Modzelewski, executive director of the NanoBusiness Alliance, said Teague is “extraordinarily competent.”

“He’s been doing this stuff forever,” Modzelewski said. “Aside from being a competent manager, he’s also very likeable. So it’s a great combination.”

Ideally, he said, Teague will toil to make the office “not something that mirrors a National Science Foundation program, which is funding universities, but looking at business.”

The office should “play this role in the center making sure all of the pieces of the government know about it and are moving forward with it.”

June 19, 2003 – Belfast, Ireland – Amphion, a provider of semiconductor IP cores, has closed a $5 million round of funding led by ACT Venture Capital, the largets VC investor in Ireland, and Invest Northern Ireland Enterprise Equity.

The company will use the funds to expand sales and support of its SIP for digital video and image coding system-on-chip design. Amphion was spun off from The Queen’s University of Belfast in 1994.

June 19, 2003 — Nanosolar Inc., a Palo Alto, Calif., developer of solar electricity cells, announced it closed on $5 million in first-round equity funding and $1.5 million in lease financing.

The round was led by U.S Venture Partners and Benchmark Capital. Stanford University and unnamed individuals also participated, according to a news release. The company secured its lease financing from Western Technology Investment.

Nanosolar will use the funds for product and business development. The company was founded in October 2001. It uses self-assembling nanostructures and organic photovoltaic technologies originally developed and licensed from Sandia National Laboratories.

JUNE 17–KUALA LUMPUR, Malaysia — The chief of the World Health Organization declared Tuesday that SARS has been “stopped dead in its tracks,” but experts said China holds the key to whether it resurfaces.

Meanwhile, the U.N. agency lifted a month-old warning to avoid nonessential travel to Taiwan, underscoring claims of success in the global fight against the illness. The only such warning still in effect is for Beijing.

Gro Harlem Brundtland, the WHO director-general, told The Associated Press that the world has stopped the spread of severe acute respiratory syndrome in the nearly 100 days since international health authorities sounded the first global alert.

“We have seen SARS stopped dead in its tracks,” Brundtland told more than 1,000 international researchers, officials and health experts meeting in Kuala Lumpur to discuss lessons learned from the outbreak.

The spread of the pneumonia-like disease by air travel highlighted the dangers of an infectious outbreak in the globalized age, she said. Nations that fail to make prompt, open disclosures risk their international credibility, she added.

Brundtland did not point a finger directly at China, but she was clearly referring to Beijing’s initial attempts to downplay its outbreak, which led to a shake-up at its Health Ministry. Brundtland praised China’s “change in opinion about what was necessary.”

Travel advisories have been lifted for several Chinese provinces, but there was no indication when Beijing might be cleared. The capital still has many SARS cases, senior WHO officials said, though they consider the outbreak to be largely contained.

David Heymann, WHO executive director on communicable diseases, said the question of a big SARS reappearance depends largely on China, where it originated. Chinese officials acknowledge at least 5,327 probable cases and 346 deaths as of Monday.

“China certainly is the key to this outbreak in many respects,” Heymann said. “Particularly because China has been able to contain this outbreak.”

SARS has killed about 800 people and sickened more than 8,400 since first being detected in southern China in November. New cases spiked in March and April, but have plunged in recent weeks.

Dr. Paul Gully, director general of Canada’s health department, said even heightened surveillance and rapid response mechanisms introduced after SARS broke out in Toronto weren’t enough to prevent a second cluster of cases in late May.

“It’s really apparent that the ember can continue to smolder and the disease recur,” Gully told the conference.

Gao Qiang, China’s vice minister of health, acknowledged that China’s initial response to the SARS outbreak was “inadequate.” He refused to comment on the travel warning for Beijing, but showed diplomatic goodwill to Taiwan, something rare between the bitter rivals.

“I would like to congratulate them, because we are all Chinese,” Gao told reporters. “It’s good for the recovery of Taiwan’s tourism industry and economic development.”

After mainland China and Hong Kong, Taiwan was hit hardest SARS, racking up 697 cases, including 83 deaths.

Taiwan was attending its first WHO event in 30 years. The island’s membership has long been blocked by China, which regards Taiwan as part of its territory following a split amid civil war in 1949. Beijing opposes any bid by the self-governing island to join international organizations.

Last week, WHO rejected two Taiwanese requests to be dropped from its travel warning list. Some Taiwanese officials suspected that China was trying to pressure WHO to take Beijing and Taiwan off at the same time.

“If the travel advisory was not removed, Taiwan’s economy could not stand much longer,” said Dr. Su Ih-jen, Taiwan’s director of disease control.

SARS will not be the last unusual disease to strike humans, health officials said. The recent U.S. outbreak of monkeypox should be a warning, said Dr. James Hughes, director for infectious diseases at the U.S. Centers for Disease Control.

Hughes said the prairie dog had been identified as the likely source of the outbreak, probably picking it up from imported animals from Africa. No one has died of the disease since it was detected in the United States last month, but at least 15 people have been infected.

Kyma gets more funding


June 16, 2003

June 11, 2003 – Kyma Technologies, Research Triangle Park, NC, a supplier of GaN substrates, has obtained $4 million in new venture capital funding, with which it plans to add staff and build a new fab space in North Carolina. Digital Power Capital and Siemens Venture Capital co-led the funding, which was also supported by former Kyma investors.

Kyma supplies 2-in. GaN wafers to semiconductor companies, including Osram Opto Semiconductors, a subsidiary of Siemens AG. Other companies such as Nitronex also work with GaN substrates, but bulk production may still be several years away, according to analysts.

Silicon Valley research firm Strategies Unlimited is expected to release new data predicting the market for GaN devices to more than quadruple in the next four years to $4.5 billion. Target markets include communications, microelectronics, and optoelectronics, where LED monitors have used GaN materials for several years.

June 16, 2003 – Asian foundries are extending their lead in the global chipmaking industry, according to a recent report from Gartner Inc., Stamford, CT.

Led by Taiwan, which contributes 83% of the region’s output, the Asia Pacific region’s share of the worldwide chipmaking industry has climbed to nearly 80%, generating revenues of more than $8 billion. Last year the Asia-Pacific region held 78.1% market share. Gartner predicts the region will continue grow another 23% in 2003, to at least $10 billion.

The report also projects wafer shipments to increase by 26% and average selling price by 2%, quarter over quarter. Gartner analyst Tan Kay-Yang, author of the report, warns that despite improvements in the SARS epidemic and geopolitical uncertainty in the Middle East, the chipmaking market is not yet out of the woods.

“The overall semiconductor business sentiment continues to appear highly capricious and volatile in the second half,” he said.

Click here to enlarge image

June 16, 2003 — When your goal is to make the blind see, the last thing you want is hype.

Click here to enlarge image

Optobionics Corp. is doing its best to avoid hype these days as it shepherds its Artificial Silicon Retina, a 2-millimeter-wide chip packed with 5,000 tiny photodiodes, through the arduous process of regulatory approval. A decade of safety tests on animals was followed by three years of safety testing in humans, and another two or three years of testing is coming up — this time to establish how well the chip works as well as how safe it is over several years.

Click here to enlarge image

The latest results are promising: None of the 10 patients in the safety test have had any problems so far with the implant, which is inserted under the damaged area of the retina. All 10 upgraded their vision, said company co-founder Alan Chow, a pediatric ophthalmologist. One who had seen only darkness can make out blurry shapes; another who had been at the blurry-shape stage can distinguish between the teams at a basketball game. Another who had only been able to make out his hand in front of his face can read 25 letters on an eye chart and see cars well enough to comment on how ugly they’ve become. The results will be published later this year in a major peer-reviewed ophthalmology journal.

Click here to enlarge image

The Naperville, Ill.-based company has moved with deliberation since its official founding in 1997 by Chow and his brother Vincent, an electrical engineer. “The company was in the basement of Alan’s house until last year,” said acting Chief Executive Officer Stuart Randle, who came on board to manage the company from one of its investors, Advanced Technology Ventures.

The brothers have been working since the late 1980s on a way to use electrical stimulation of the retina to help patients with retinitis pigmentosa (RP) and age-related macular degeneration (AMD), two conditions where retinal cells are damaged and for which there is currently no cure. Such stimulation produces flashes of light even for people with vision loss, and the Chows designed an implant that can create thousands of flashes that function like the pixels in a television screen to create a picture. The microphotodiodes in Optobionics’ implant are powered by the light that comes into the eye, like solar cells.

All the patients in the trials have RP, but AMD is by far the more common of the two diseases, with 10 million victims in the United States. alone. Clinical trials with AMD patients are in the company’s long-term plan.

Among the company’s investors are venture capital firms like Arch Venture Partners and Polaris Venture Partners, and Medtronic Inc. and Ciba Vision, powerhouses of medical implants and vision care respectively. They’ve committed a total of $30 million so far.

It’s the right set of backers to take the product to market, said Robert Paull, a managing partner at the nanotech venture firm Lux Capital, who has been following Optobionics’ fortunes. “There’s a reason the guy was called ‘The Six-Million-Dollar Man’ — these devices are expensive,” he said. But if insurers can be persuaded to pay for the device, “Optobionics may really have something.”

Medtronic, the world’s largest medical implant company, has contributed a member to Optobionics’ board: Steve Oesterle, senior vice president of medicine technology. He offers the benefit of Medtronic’s experience in areas like designing an effective controlled study for a medical device (where insertion of a sham device — the equivalent of a placebo in a pharmaceutical study — may be impractical or ethically unacceptable), and how to made the device economically viable. “The FDA only evaluates safety and efficacy, not whether a device is cost-effective,” he said. “We have to clearly think through how to design a trial that will convince CMS (Medicare’s governing agency) to reimburse for it.”

Chow estimates that at least a dozen groups around the world — many of them academic researchers — are working on some kind of retinal implant technology. Only one U.S. company, Second Sight LLC in Sylmar, Calif., has gotten as far as clinical trials, and it has put implants in two patients so far.

The most promising development is one that Chow didn’t expect: The chip seems to stimulate the retinal cells around it, so that the improvements in vision come as much from the patients’ own cells as from the implant, or maybe even more.

“It now seems to be a therapeutic device,” he said. “If it’s implanted early enough, it could stop the impact of these diseases.”


null

Company file: Optobionics Corp.
(last updated June 16, 2003)

Company
Optobionics Inc.

Headquarters
850 East Diehl Road, Suite 120
Naperville, IL 60563-9386

History
Optobionics was incorporated in January 1990 by Alan and Vincent Chow, but sat dormant until 1997, when it received outside funding.

Industry
Implantable medical devices

Employees
15

Small tech-related products and services
Optobionics is developing an artificial retina that is currently in clinical trials. The silicon-based surgically implantable chip contains thousands of ultraminiature diodes that react to light levels and emit appropriate voltage levels to induce visual signals.

Management

  • Stuart Randle: acting chief executive officer
  • Alan Chow: chief scientific officer
  • Vincent Chow: vice president of engineering
  • Peter Lord: vice president of development
  • Investment history
    In mid-June 1997 Optobionics picked up $750,000 in seed funding from ARCH Venture Partners, Polaris Venture Partners and Advanced Technology Ventures and Polaris. Second-round funding was completed in June 2000, in the amount of $4.4 million. Polaris, ARCH and ATV all participated, as well as newcomer Ciba Vision, which led the round. Optobionics garnered an additional $20 million in December 2001, with funding from ATV, ARCH, Medtronic and Polaris.

    Barriers to market
    Like other firms in the medical device sector, Optobionics has to deal with extensive FDA testing — more than 10 years with animal trials and five or six with human clinical trials. On top of that, Optobionics needs to find a way to determine the cost-effectiveness of their product.

    Selected competitors
    Second Sight LLC, a California-based company, is also testing a retinal implant. VisionCare Ophthalmic Technologies, also headquartered in California, is in clinical trials with an implantable ophthalmic telescope to address macular degeneration.

    Goals
    Short-term: To work with the FDA to design a clinical trial to prove the safety and efficacy of the Artificial Silicon Retina in patients with retinitis pigmentosa. Long-term: To market a working retinal implant for patients with both RP and age-related macular degeneration, a much-more-common condition with a huge potential market.

    Why they’re in small tech
    “An 11-year-old boy came into my office thinking he had gotten something in his eye, and it turned out to be RP,” said Alan Chow. “It was frustrating — there wasn’t much I could do for him except watch him go blind.”

    What keeps them up at night
    Acting CEO Stuart Randle: “Being on completely new frontiers in both technology and medicine. ” Alan Chow: “Sheer excitement. I can start an operation at 8 a.m., finish it at 3 am, and go out and talk about it afterwards.”

    Relevant patents

  • Artificial retina device with stimulating and ground return electrodes disposed on opposite sides of the neuroretina and method of attachment
  • Multi-phasic microphotodetector retinal implant with variable voltage and current capability
  • Relevant articles
    Obstacles clutter path for implant sector
    Implanted microsystems are key to restoring sight to the blind
    Company sees success and funding in helping to give sight to the blind

    Contact

  • URL: www.optobionics.com
  • Phone: 630-245-0614
  • Fax: 630-245-060
  • E-mail: [email protected]
  • — Research by Gretchen McNeely